WebA total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to … WebMost patients empirically received antipseudomonal β-lactams, and the only significant difference was that a larger number of patients in the ESBL group had received meropenem compared with the non-ESBL group (22% vs. 2%, p < 0.001) ( Table 2 ). Of the 11 patients who were empirically prescribed meropenem, 6 had a history of an ESBL infection.
Meropenem Versus Piperacillin-Tazobactam for Definitive …
WebOct 1, 2024 · Statistical adjustment within subgroups did not affect the primary outcome, as the noninferiority margin was not met and meropenem was favored in all subgroups. … WebApr 17, 2024 · In the MERINO trial, 30-day mortality was higher in patients with ESBL ... targeting bacterial enzymes involved in DNA replication. 9,10 Fluoroquinolone-resistant strains of Pseudomonas avoid this effect by mutating ... Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or ... dr wendy neal
PRIME PubMed Effect of Piperacillin-Tazobactam vs Meropenem …
WebApr 21, 2024 · Comparisons are piperacillin-tazobactam vs. meropenem. Primary Outcomes All-cause mortality at 30 days 12.3% vs 3.7% (risk difference 8.6%; 97.5% CI negative … WebThe MERINO trial demonstrated a mortality benefit for meropenem vs piperacillin/tazobactam in bacteremia. However, a post-hoc analysis found that the mortality benefit was attenuated when the piperacillin minimum inhibitory concentration was … WebAug 2, 2024 · Effects were consistent in an analysis of the per-protocol population. Within the subcomponents of the primary outcome, 5 of 38 (13%) experienced microbiological … dr wendy moore wake forest pulmonary